These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10745629)

  • 1. Successful bone marrow transplantation in an adult patient with reactive hemophagocytic syndrome associated with myelodysplastic syndrome.
    Karasuno T; Teshima H; Hiraoka A; Nakamura H; Masaoka T
    Int J Hematol; 2000 Feb; 71(2):180-3. PubMed ID: 10745629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful bone marrow transplantation from an HLA-identical unrelated donor in a patient with hemophagocytic lymphohistiocytosis.
    Adachi S; Kubota M; Akiyama Y; Kato T; Kitoh T; Furusho K
    Bone Marrow Transplant; 1997 Jan; 19(2):183-5. PubMed ID: 9116618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of hemophagocytic lymphohistiocytosis with prolonged remission after syngeneic bone marrow transplantation.
    Hasegawa D; Sano K; Kosaka Y; Hayakawa A; Nakamura H
    Bone Marrow Transplant; 1999 Aug; 24(4):425-7. PubMed ID: 10467334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
    Malladi RK; Peniket AJ; Norton AE; Campbell AJ; Collins GP; Samol J; Eagleton H; Miller E; Morgenstern G; Jones J; Keen-Mcguire A; Barnardo M; Littlewood TJ
    Eur J Haematol; 2004 Aug; 73(2):85-92. PubMed ID: 15245506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin.
    Komeno Y; Kanda Y; Kandabashi K; Kawazu M; Goyama S; Takeshita M; Nannya Y; Niino M; Nakamoto T; Kurokawa M; Tsujino S; Ogawa S; Aoki K; Chiba S; Motokura T; Hirai H
    Am J Hematol; 2003 Mar; 72(3):220-2. PubMed ID: 12605397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic bone marrow transplantation for children with myelodysplastic syndrome.
    Uçkan D; Cetin M; Hiçsönmez G; Tezcan I; Tuncer AM
    Turk J Pediatr; 2000; 42(3):192-7. PubMed ID: 11105616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome.
    Depil S; Deconinck E; Milpied N; Sutton L; Witz F; Jouet JP; Damaj G; Yakoub-Agha I;
    Bone Marrow Transplant; 2004 Mar; 33(5):531-4. PubMed ID: 14716345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
    Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
    Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation for myelodysplastic syndrome--who? when? and which?
    Luger S; Sacks N
    Bone Marrow Transplant; 2002 Aug; 30(4):199-206. PubMed ID: 12203135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow transplantation in Shwachman-Diamond syndrome.
    Hsu JW; Vogelsang G; Jones RJ; Brodsky RA
    Bone Marrow Transplant; 2002 Aug; 30(4):255-8. PubMed ID: 12203143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
    Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
    Ogasawara T; Yasuyama M; Kawauchi K
    Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful rapid discontinuation of immunosuppressive therapy at molecular relapse after allogeneic bone marrow transplantation in a pediatric patient with myelodysplastic syndrome.
    Tamura K; Kanazawa T; Suzuki M; Koitabashi M; Ogawa C; Morikawa A
    Am J Hematol; 2006 Feb; 81(2):139-41. PubMed ID: 16432864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Improvement of diabetes insipidus after allogeneic bone marrow transplantation in a patient with myelodysplastic syndrome].
    Sato N; Takayama N; Kizaki M; Ikeda Y; Okamoto S
    Rinsho Ketsueki; 2003 May; 44(5):318-22. PubMed ID: 12822406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation in myelodysplastic syndromes.
    de Witte T; Suciu S; Brand R; Muus P; Kröger N
    Semin Hematol; 2007 Oct; 44(4):274-7. PubMed ID: 17961727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplant strategies for patients with myelodysplastic syndromes.
    Deeg HJ
    Curr Opin Hematol; 2006 Mar; 13(2):61-6. PubMed ID: 16456370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.